Key Highlights
- Jon Garen joins Ensoma as Chief Corporate Development and Business Officer
- Garen’s experience spans genomic medicines, oncology, and rare diseases
- First IND submission expected next year for pioneering in vivo HSC-targeted gene therapy
- Garen’s background includes strategic roles at Dunad Therapeutics, Nocion Therapeutics, and uniQure
Source: Business Wire
Notable Quotes
- “Jon is an accomplished leader with an exceptional track record in genetic medicines and business development… as we prepare for our first IND submission next year—representing the first in vivo HSC-targeted gene therapy in humans.” — Jim Burns, CEO at Ensoma
- “The potential of Ensoma’s in vivo platform to revolutionize genetic treatments – and potential cures for patients and their families – is truly exciting.” — Jon Garen, Chief Corporate Development and Business Officer at Ensoma
SoHC's Take
Ensoma’s recent appointment of Jon Garen signifies the company’s strategic readiness to transition into clinical development, particularly as it targets its first IND submission for a unique in vivo HSC-targeted gene therapy. Garen’s impressive track record, notably at uniQure with its pivotal hemophilia B gene therapy partnership, underscores his capability to drive Ensoma’s growth. With Ensoma’s innovative approach in genomic medicine and Garen’s expertise in securing transformative partnerships, Ensoma is well-positioned to make substantial advancements in precision genetic medicine, poised to impact genetic diseases and immune disorders. This appointment reflects the company’s ambitions to solidify its leadership in next-generation gene therapies.
